Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore

Published:2020-12 Issue:2 Volume:1874 Page:188420
ISSN:0304-419X
Container-title:Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
language:en
Short-container-title:Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

Author:

Li Rui,Han Dongsheng,Shi Jiping,Han YanXi,Tan Ping,Zhang Rui,Li Jinming

Funder

National Key R&D Program of China

Beijing Dongcheng District Outstanding Talents Team Program

Publisher

Elsevier BV

Subject

Cancer Research,Genetics,Oncology

Reference146 articles.

1. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer;Ricciuti;J. Immunother. Cancer.,2019

2. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma;Motzer;N. Engl. J. Med.,2018

3. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer;Antonia;N. Engl. J. Med.,2017

4. Nivolumab plus ipilimumab in advanced melanoma;Wolchok;N. Engl. J. Med.,2013

5. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial;Rosenberg;Lancet (London, England).,2016

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Construction of an autophagy-related genes risk model as predicting prognosis: BAG1 suppresses growth of clear cell renal cell carcinoma;International Immunopharmacology;2024-10

2. The neoantigens derived from transposable elements – A hidden treasure for cancer immunotherapy;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

3. S100A9, as a potential predictor of prognosis and immunotherapy response for GBM, promotes the malignant progression of GBM cells and migration of M2 macrophages;Aging;2024-06-19

4. Harmonizing tumor mutational burden analysis: Insights from a multicenter study using in silico reference data sets in clinical whole-exome sequencing (WES);American Journal of Clinical Pathology;2024-05-12

5. Advanced gallbladder cancer with high tumor mutation burden: a case report and literature review;AME Case Reports;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3